Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a breakthrough in Huntington’s disease, a $175 million capital infusion, and a reaffirmed “buy” rating from Stifel. These tailwinds made investors recalibrate the company’s











